title: Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells.
abstract: Efficient generation of competent vasculogenic cells is a critical challenge of human induced pluripotent stem (hiPS) cell-based regenerative medicine. Biologically relevant systems to assess functionality of the engineered vessels in vivo are equally important for such development. Here, we report a unique approach for the derivation of endothelial precursor cells from hiPS cells using a triple combination of selection markers--CD34, neuropilin 1, and human kinase insert domain-containing receptor--and an efficient 2D culture system for hiPS cell-derived endothelial precursor cell expansion. With these methods, we successfully generated endothelial cells (ECs) from hiPS cells obtained from healthy donors and formed stable functional blood vessels in vivo, lasting for 280 d in mice. In addition, we developed an approach to generate mesenchymal precursor cells (MPCs) from hiPS cells in parallel. Moreover, we successfully generated functional blood vessels in vivo using these ECs and MPCs derived from the same hiPS cell line. These data provide proof of the principle that autologous hiPS cell-derived vascular precursors can be used for in vivo applications, once safety and immunological issues of hiPS-based cellular therapy have been resolved. Additionally, the durability of hiPS-derived blood vessels in vivo demonstrates a potential translation of this approach in long-term vascularization for tissue engineering and treatment of vascular diseases. Of note, we have also successfully generated ECs and MPCs from type 1 diabetic patient-derived hiPS cell lines and use them to generate blood vessels in vivo, which is an important milestone toward clinical translation of this approach.
authors.affiliation: Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
authors.forename: Rekha
authors.initials: R
authors.lastname: Samuel
authors.forename: Laurence
authors.initials: L
authors.lastname: Daheron
authors.forename: Shan
authors.initials: S
authors.lastname: Liao
authors.forename: Trupti
authors.initials: T
authors.lastname: Vardam
authors.forename: Walid S
authors.initials: WS
authors.lastname: Kamoun
authors.forename: Ana
authors.initials: A
authors.lastname: Batista
authors.forename: Christa
authors.initials: C
authors.lastname: Buecker
authors.forename: Richard
authors.initials: R
authors.lastname: Schäfer
authors.forename: Xiaoxing
authors.initials: X
authors.lastname: Han
authors.forename: Patrick
authors.initials: P
authors.lastname: Au
authors.forename: David T
authors.initials: DT
authors.lastname: Scadden
authors.forename: Dan G
authors.initials: DG
authors.lastname: Duda
authors.forename: Dai
authors.initials: D
authors.lastname: Fukumura
authors.forename: Rakesh K
authors.initials: RK
authors.lastname: Jain
mesh_terms: D000818:Animals; D001807:Blood Vessel Prosthesis; D042783:Endothelial Cells / Q000378:metabolism* / Q000637:transplantation; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology / Q000378:metabolism* / Q000637:transplantation; D051379:Mice; D016513:Mice, SCID; D018919:Neovascularization, Physiologic; D023822:Tissue Engineering; D014183:Transplantation, Heterologous; D014652:Vascular Diseases / Q000628:therapy
keywords: diabetes; reprogramming; vascular endothelial cells